title: The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma.
abstract: For decades, no cancer therapy had been shown to improve average survival in metastatic melanoma. Two critical events have occurred, the discovery of melanoma driver mutation subsets and the discovery of immune checkpoint inhibitors, which have allowed for the development of modern, effective therapies. These findings have facilitated a rapid emergence of novel therapeutics for the disease with multiple FDA approvals in the last several years. The drugs vemurafenib, trametinib, and dabrafenib, which inhibit the commonly mutated BRAF pathway, have been approved based on improvements in survival outcomes. Agents that block immune checkpoints on lymphocytes allowing for immune cell activity against melanoma have also been approved based on improved survival outcomes such as ipilimumab and nivolumab. Pembrolizumab, another immune checkpoint inhibitor, has also been approved based on the response rate and duration of response in a phase 1 trial. Further agents and combinations of approved agents are positioned to possibly further increase this tally of approved drugs. This review will discuss recently approved novel agents and select drugs in development in advanced melanoma.
authors.affiliation: Baylor-Sammons Cancer Center, Texas Oncology, P.A., Dallas, TX, USA.
authors.forename: Lijo
authors.initials: L
authors.lastname: John
authors.affiliation: Baylor-Sammons Cancer Center, Texas Oncology, P.A., Dallas, TX, USA. Lance.Cowey@USOncology.com.|Skin Malignancy Treatment and Research Center, Baylor University Medical Center, 3410 Worth Street, Dallas, TX, USA. Lance.Cowey@USOncology.com.|US Oncology Research, Dallas, TX, USA. Lance.Cowey@USOncology.com.
authors.forename: C Lance
authors.initials: CL
authors.lastname: Cowey
keywords: Dabrafenib; Immune checkpoint inhibitor; Immunotherapy; Ipilimumab; Metastatic melanoma; Nivolumab; Pembrolizumab; Targeted therapy; Trametinib; Vemurafenib